Objectives Beta blockers reduce mortality in heart failure (HF). However, it is not clear whether they should be temporarily withdrawn during acute HF.
Design Analysis of prospectively collected data.
Setting The Gulf aCute heArt failuRe rEgistry is a prospective multicentre study of patients hospitalised with acute HF in seven Middle Eastern countries.
Participants 5005 patients with acute HF.
Outcome measures We studied the effect of beta blockers non-withdrawal on intrahospital, 3-month and 12-month mortality and rehospitalisation for HF in patients with acute decompensated chronic heart failure (ADCHF) and acute de novo heart failure (ADNHF) and a left ventricular ejection fraction (LVEF) <40%.
Results 44.1% of patients were already on beta blockers on inclusion. Among those, 57.8% had an LVEF <40%. Further, 79.9% were diagnosed with ADCHF and 20.4% with ADNHF. Mean age was 61 (SD 13.9) in the ADCHF group and 59.8 (SD 13.8) in the ADNHF group. Intrahospital mortality was lower in patients whose beta blocker therapy was not withdrawn in both the ADCHF and ADNHF groups. This protective effect persisted after multivariate analysis (OR 0.05, 95% CI 0.022 to 0.112; OR 0.018, 95% CI 0.003 to 0.122, respectively, p<0.001 for both) and propensity score matching even after correcting for variables that remained significant in the new model (OR 0.084, 95% CI 0.015 to 0.468, p=0.005; OR 0.047, 95% CI 0.013 to 0.169, p<0.001, respectively). At 3 months, mortality was still lower only in patients with ADCHF in whom beta blockers were maintained during initial hospitalisation. However, the benefit was lost after correcting for confounding factors. Interestingly, rehospitalisation for HF and length of hospital stay were unaffected by beta blockers discontinuation in all patients.
Conclusion In summary, non-withdrawal of beta blockers in acute decompensated chronic and de novo heart failure with reduced ejection fraction is associated with lower intrahospital mortality but does not influence 3-month and 12-month mortality, rehospitalisation for heart failure,and the length of hospital stay.
Trial registration number NCT01467973; Post-results.
- heart failure
- adult cardiology
- cardiac epidemiology
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Statistics from Altmetric.com
Contributors KS, KFA, NA, AA-A, MA-J, BB, WA, MR, NB, HA, AA-M, HAF, AE, PP and JAS were involved in the design of the Gulf CARE registry and patient enrolment and ensuring quality control of the study. CAK designed the analysis and wrote the manuscript. ZM and RS carried out the statistical analyses. All authors approved the final version of the manuscript.
Funding Gulf CARE is an investigator-initiated study conducted under the auspices of the Gulf Heart Association and funded by Servier, Paris, France and (for centres in Saudi Arabia) by the Saudi HeartAssociation. Dr Abi Khalil’s lab is funded by the Biomedical Research Program (BMRP) at Weill Cornell Medicine-Qatar, a programme funded by Qatar Foundation, and by two grants from the Qatar National Research Funds under its National Priorities Research Program award numbers (NPRP 7 - 701 - 3 – 192 and NPRP 9-169-3-024). Dr Al-Habib’s lab is funded by the Saudi Heart Association and The Deanship of Scientific Research at King Saud University, Riyadh, Saudi Arabia (research group number: RG -14360-013).
Disclaimer The funders did not have a role in the study’s concept, analysis and writing of the manuscript.
Competing interests None declared.
Patient consent Obtained.
Ethics approval The registry protocol was approved by each participating centre’s institutional review board.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement The data include human data. To protect participant privacy, the data are available on request from the corresponding author.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.